ClinicalTrials.gg
CompletedNCT07823140Updated Oct 5, 2026

Effects of Kudzu Root (Gegen) on Drug-Metabolizing Enzymes and Blood Clotting in Healthy Volunteers

A Phase 1 interventional study of Arm 1: Radix Puerariae lobatae (Gegen) and Arm 1: Six-probe drug cocktail in Herb-drug Interactions, sponsored by Chinese University of Hong Kong. Completed at 1 site in Hong Kong. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Chinese University of Hong Kong · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 4 years after the study started (first participant enrolled Aug 2022, registered Sep 2026).
Updated Oct 5, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Study summary

Purpose:

The purpose of this study is to understand how the traditional herbal medicine kudzu root (Gegen, Radix Puerariae lobatae) affects the activity of drug metabolizing enzymes in the body, and whether this could lead to interactions with other medicines.

Background:

Many medicines are broken down in the body by enzymes called cytochrome P450 (CYP) enzymes. Preclinical data suggest that Gegen can inhibit CYP enzymes, which may lead to herb-drug interactions; however, robust clinical evidence in humans remains insufficient.

Participants:

This study recruited 56 healthy Chinese adults, who were randomly assigned to parallel low and high dose Gegen groups; 52 participants finished the study.

Interventions:

Participants took a mixture of probe medicines known as a CYP probe cocktail to measure baseline CYP enzyme activity. After receiving either low or high dose Gegen, they received the probe cocktail again to detect changes in enzyme activity. Blood samples were collected to test the probe medicines, their breakdown products, and markers for blood clotting and blood vessel health.

Outcome Measures:

Primary outcomes include changes in blood levels and metabolic ratios of probe medicines. These values reflect differences in CYP enzyme activity with and without Gegen, and are compared across low and high dose groups.

Hypothesis:

The study hypothesized that Gegen alters CYP enzyme activity, and that the magnitude of this effect varies with Gegen dose.

Read the detailed description

Gegen (Radix Puerariae lobatae) is a common traditional Chinese herbal medicine. Preclinical data indicate its potential to inhibit cytochrome P450 enzymes, which may lead to herb-drug interactions. However, robust clinical evidence in humans remains insufficient.This randomized, two-period study enrolled healthy Chinese adults, with participants allocated to parallel low-dose and high-dose Gegen groups. A six-probe drug cocktail was administered before and after Gegen intake to characterize in vivo CYP enzyme activity under intervention and control conditions.Serial blood samples were collected to quantify probe substrates and metabolites for CYP phenotyping, and to measure circulating biomarkers of coagulation and endothelial function for safety assessment. This study evaluated Gegen's effects on six key human CYP isoforms (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A). Enzyme activity was assessed using metabolic ratios and AUC-based drug exposure comparisons. Specific coagulation and endothelial biomarkers, including thromboxane B2 and soluble thrombomodulin, were examined. Adverse events were monitored throughout the study.The results of this study provide insight into the isoform-specific modulation of CYP enzymes by Gegen and its potential implications for herb-drug interactions involving CYP-metabolized medications.

02

Conditions studied

  • Herb-drug Interactions

Keywords

  • Kudzu root
  • Gegen
  • Pueraria lobata
  • Herb-drug interaction
  • Cytochrome P450
  • CYP2C19
  • Probe drug cocktail
  • Traditional Chinese medicine
03

In context

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,455 studies on the registry; 475 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and non-pregnant female Chinese subjects, 20 - 45 years of age.
  2. Body weight within 15% of ideal weight (according to the Metropolitan Insurance Company Bulletin).
  3. Accessible vein for blood sampling.
  4. High probability for compliance and completion of the study.
  5. Female subjects who are surgically sterile or . Or female subjects of child bearing potential agree to practice abstinence or take effective methods (e.g. non-hormonal intra-uterine device, consistent condom plus spermicide use or consistent cervical cap with spermicide) from the start of screening until two weeks of last dose administration to prevent pregnancy.
  6. Male subjects agree to practice abstinence or take effective contraceptive method (refer to the aforementioned) from the start of screening until two weeks of last dose administration to prevent his partner pregnant.
  7. Subjects agree to abstain from any prescription or non-prescription medications 2 weeks before the first dosing and throughout the study (except those allowed based on investigator's judgement).
  8. Have signed the written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. hepatic, renal, biliary, cardiovascular, gastrointestinal, haematological and other chronic and acute diseases within 3 months prior to the study.
  2. Clinically significant abnormality in physical examination, evaluation, urine test, blood chemistry or haematological test.
  3. Tobacco uses in any forms.
  4. Positive results of .
  5. Regular consumer of alcohol (on average more than one drink per day within 1 month prior to the start of first dosing).
  6. Consumer of Asian vegetables, fruits or other herb medicine which are known to contain moderate to high levels of furanocoumarins, such as grapefruit juice, or herbal teas that naturally contain coumadin or coumadin-like substances such as Chamomile tea.
  7. Have lost or donate more than 350 ml blood donation within 4 weeks prior to the start of the study.
  8. Administer any prescription or non-prescription medications which is likely to be required during the course of the study (except those allowed based on investigator's judgement).
  9. Treatment of Gegen or the studied probe drugs (caffeine, losartan, omeprazole, metoprolol, midazolam, efavirenz) within 2 weeks before the study.
  10. Volunteer in any clinical drug study within 1 month prior to this study
  11. History of allergy or to Gegen or the studied probe drugs (caffeine, losartan, omeprazole, metoprolol, midazolam, efavirenz) and other drugs in its class.
  12. History of drug abuse in any form.
  13. Female subjects who are breastfeeding or pregnancy.
  14. Subjects who are considered not suitable in participating the study due to other unfavourable factors determined by investigators.
  15. History or presence of problem in swallowing capsules and/or Chinese medicine.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Low dose Gegen

    Participants received the low-dose (3.3 g) Gegen regimen for 14 days; the six-probe drug cocktail was administered once before (Session I, baseline) and once after (Session II) Gegen dosing for CYP phenotyping.

    Drug: Arm 1: Radix Puerariae lobatae (Gegen) · Drug: Arm 1: Six-probe drug cocktail

  • Experimental
    High dose Gegen

    Participants received the high-dose (5 g) Gegen regimen for 14 days; the six-probe drug cocktail was administered once before (Session I, baseline) and once after (Session II) Gegen dosing for CYP phenotyping.

    Drug: Arm 2: Radix Puerariae lobatae (Gegen) · Drug: Arm 2: Six-probe drug cocktail

Interventions

  • DrugArm 1: Radix Puerariae lobatae (Gegen)

    Granules of the dried root of Pueraria lobata (listed in the Hong Kong Chinese Materia Medica Standards; Chinese Pharmacopoeia monograph Radix Puerariae Lobatae).

    Also known as: Puerariae Lobatae Radix, Kudzu Root, Lobed Kudzuvine Root

  • Single oral dose of a cocktail comprising caffeine (CYP1A2), efavirenz (CYP2B6), losartan (CYP2C9), omeprazole (CYP2C19), metoprolol (CYP2D6), and midazolam (CYP3A4).

    Also known as: caffeine, efavirenz, losartan, omeprazole, metoprolol, midazolam

  • DrugArm 2: Radix Puerariae lobatae (Gegen)

    Granules of the dried root of Pueraria lobata (listed in the Hong Kong Chinese Materia Medica Standards; Chinese Pharmacopoeia monograph Radix Puerariae Lobatae).

    Also known as: Puerariae Lobatae Radix, Kudzu Root, Lobed Kudzuvine Root

  • Single oral dose of a cocktail comprising caffeine (CYP1A2), efavirenz (CYP2B6), losartan (CYP2C9), omeprazole (CYP2C19), metoprolol (CYP2D6), and midazolam (CYP3A4).

    Also known as: caffeine, efavirenz, losartan, omeprazole, metoprolol, midazolam

06

What researchers measure

Primary outcomes

  1. Change in CYP1A2 phenotypic activity

    Plasma concentrations of caffeine and its metabolite paraxanthine were quantified by validated LC-MS/MS. CYP1A2 activity was expressed as the AUC0-t derived metabolite-to-parent ratio (unit of measure: ratio).

    Time frame: Session I (baseline) and Session II (after 14 days of Gegen administration); within each session, blood samples were collected at pre-dose (0 hour) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours after dosing of cocktail probe drugs.

  2. Change in CYP2B6 phenotypic activity

    Plasma concentrations of efavirenz and its metabolite 8-Hydroxy-efavirenz were quantified by validated LC-MS/MS. CYP1A2 activity was expressed as the AUC0-t derived metabolite-to-parent ratio (unit of measure: ratio).

    Time frame: Session I (baseline) and Session II (after 14 days of Gegen administration); within each session, blood samples were collected at pre-dose (0 hour) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours after dosing of cocktail probe drugs.

  3. Change in CYP2C9 phenotypic activity

    Plasma concentrations of losartan and its metabolite E-3174 were quantified by validated LC-MS/MS. CYP1A2 activity was expressed as the AUC0-t derived metabolite-to-parent ratio (unit of measure: ratio).

    Time frame: Session I (baseline) and Session II (after 14 days of Gegen administration); within each session, blood samples were collected at pre-dose (0 hour) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours after dosing of cocktail probe drugs.

  4. Change in CYP2C19 phenotypic activity

    Plasma concentrations of omeprazole and its metabolite 5-Hydroxy-omeprazole were quantified by validated LC-MS/MS. CYP1A2 activity was expressed as the AUC0-t derived metabolite-to-parent ratio (unit of measure: ratio).

    Time frame: Session I (baseline) and Session II (after 14 days of Gegen administration); within each session, blood samples were collected at pre-dose (0 hour) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours after dosing of cocktail probe drugs.

  5. Change in CYP2D6 phenotypic activity

    Plasma concentrations of metoprolol and its metabolite α-Hydroxy-metoprolol were quantified by validated LC-MS/MS. CYP1A2 activity was expressed as the AUC0-t derived metabolite-to-parent ratio (unit of measure: ratio).

    Time frame: Session I (baseline) and Session II (after 14 days of Gegen administration); within each session, blood samples were collected at pre-dose (0 hour) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours after dosing of cocktail probe drugs.

  6. Change in CYP3A4 phenotypic activity

    Plasma concentrations of midazolam and its metabolite 1'-Hydroxy-midazolam were quantified by validated LC-MS/MS. CYP1A2 activity was expressed as the AUC0-t derived metabolite-to-parent ratio (unit of measure: ratio).

    Time frame: Session I (baseline) and Session II (after 14 days of Gegen administration); within each session, blood samples were collected at pre-dose (0 hour) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours after dosing of cocktail probe drugs.

  7. Change in thromboxane B2 concentration

    Plasma concentration of thromboxane B2, a biomarker of platelet activation and coagulation, was quantified by enzyme-linked immunosorbent assay (unit of measure: ng/mL).

    Time frame: Blood samples collected at pre-dose (0 hour) in Session I (baseline) and 72 hours post-cocktail-dose in Session II (after 14 days of Gegen dosing)

  8. Change in soluble thrombomodulin concentration

    Plasma concentration of soluble thrombomodulin, a biomarker of endothelial function, was quantified by enzyme-linked immunosorbent assay (unit of measure: ng/mL).

    Time frame: Blood samples collected at pre-dose (0 hour) in Session I (baseline) and 72 hours post-cocktail-dose in Session II (after 14 days of Gegen dosing)

  9. Change in prothrombin time

    Plasma prothrombin time, a coagulation parameter, was measured by standard clotting assay on an automated coagulometer (unit of measure: seconds).

    Time frame: Blood samples collected at pre-dose (0 hour) in Session I (baseline) and 72 hours post-cocktail-dose in Session II (after 14 days of Gegen dosing)

Secondary outcomes

  1. Incidence of adverse events

    Number and percentage of participants with at least one adverse event, assessed by physical examination (general appearance, skin, head, eye, ear, nose, throat, neck, heart, chest, central neurologic system, abdomen, extremity), vital signs (body temperature, pulse, respirations, sitting systolic and diastolic pressures), 12-lead electrocardiogram (heart rate, PR interval, QRS duration, QT interval), and laboratory safety tests (haematology, blood chemistry, urinalysis).

    Time frame: From enrolment until the final visit (72 hours after the Session II probe cocktail administration)

07

Study locations

1 site
  • The Chinese University of Hong Kong Phase 1 Clinical Trial Centre
    Hong Kong, Hong Kong
08

References and documents

Individual participant data

Plan to share: No — Dataset includes identifiable genotype information.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Apr 2023, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2026
First posted
Sep 16, 2026
StartActual
Aug 8, 2022
Primary completionActual
Apr 21, 2023
CompletionActual
Apr 28, 2023
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited; 1 exclusion criterion removed
What changed in the criteria
Inclusion criteria
  • EditedBody weight within 15% of ideal weight (according to the Metropolitan InsuranceCompanyInsurance Company Bulletin).
Exclusion criteria
  • RemovedGenetics of the studied six CYPs revealed no enzyme activity (homozygous), including following genetic variants: CYP2C9*25, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*35, CYP2D6*4, CYP2D6*6, CYP3A4*20.
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion removed
    What changed in the criteria
    Inclusion criteria
    • EditedBody weight within 15% of ideal weight (according to the Metropolitan InsuranceCompanyInsurance Company Bulletin).
    Exclusion criteria
    • RemovedGenetics of the studied six CYPs revealed no enzyme activity (homozygous), including following genetic variants: CYP2C9*25, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*35, CYP2D6*4, CYP2D6*6, CYP3A4*20.

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07823140
Responsible party
Zhong Zuo (Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Sep 16, 2026
Start date
Aug 8, 2022
Primary completion
Apr 21, 2023
Completion
Apr 28, 2023
Last update
Oct 5, 2026

Study contacts

Zhong Zuo, PhD
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion